Kristof Roox

The New EU "Pharma Package": Access Conditionalities And Shortage Measures – A Comparison Of Commission/Parliament/Council Positions

The New EU "Pharma Package": The "Bolar" Exemption – A Comparison Of Commission/Parliament/Council Positions

The New EU "Pharma Package": Global (Orphan) Marketing Authorization

The New EU "Pharma Package": The Debate On Fiscal Import In The Supply Chain

The New EU "Pharma Package": The Transferable Exclusivity Voucher—A Comparison Of Commission/Parliament/Council Positions

The New EU "Pharma Package": Regulatory Data Protection – A Comparison Of Commission/Parliament/Council Positions

The New EU "Pharma Package": Preparing For The Trilogues

Preparing For The EU's New Approach To Critical Medicines And Medicine Shortages: A New 'Critical Medicines Act'?

The New Urban Wastewater Treatment Directive

Preparing For The U.S. BIOSECURE Act

Brussels Court Of Appeal Prohibits The Rebranding Of A Generic Pharmaceutical Into The Originator Reference Product In The Framework Of Parallel Import

International Litigation: Litigating Patents In Europe: A Whole New Ball Game

If Louis Vuitton Cannot Prove Acquired Distinctiveness, Can You? Checking In After The Louis Vuitton ‘Damier Azur' Case

European Court Of Justice Issues Landmark Judgments Regarding Trademark Enforcement In Parallel Imports Of Generic Pharmaceuticals: No Repackaging/Rebranding As The Originator Reference Product

Unveiling The Complexity Of The Belgian MedTech Legal Landscape